Magnesium and arrhythmias after coronary artery bypass surgery

P A Casthely1, T Yoganathan, C Komer

  • 1Department of Anesthesiology and Medicine, St. Joseph's Hospital and Medical Center, Paterson, NJ 07503.

Insights

Magnesium administration before and after cardiac surgery significantly reduced arrhythmias in patients undergoing coronary artery bypass grafting (CABG). This intervention proved effective for both hypokalemic and normokalemic individuals.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Pharmacology

Background:

  • Post-cardiac surgery arrhythmias are common and multifactorial.
  • Magnesium is increasingly recognized for its role in managing supraventricular and ventricular arrhythmias.

Purpose of the Study:

  • To evaluate the efficacy of magnesium in preventing arrhythmias after coronary artery bypass grafting (CABG).
  • To assess magnesium's role in both hypokalemic and normokalemic patients with normal renal and ventricular function.

Main Methods:

  • 140 patients undergoing CABG were divided into four groups: control, magnesium before cardiopulmonary bypass (CPB), magnesium after CPB, and magnesium before and after CPB.
  • Serum potassium, catecholamine, magnesium levels, and arrhythmia incidence were measured.
  • Patients were categorized as hypokalemic (K < 3.5 mEq/L) or normokalemic (K > 3.5 mEq/L).

Main Results:

  • The incidence of arrhythmias was significantly lower in the group receiving magnesium before and after CPB (1 patient) compared to other groups (12 in control, 14 in pre-CPB, 5 in post-CPB).
  • Magnesium levels were highest in the group that received magnesium both before and after CPB.
  • No significant difference in magnesium levels was observed between hypokalemic and normokalemic patients within groups.

Conclusions:

  • Administering magnesium sulfate before and after cardiac surgery effectively reduces the incidence of arrhythmias in patients undergoing CABG.
  • Magnesium supplementation is beneficial for both hypokalemic and normokalemic patients post-CABG.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...